Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome

Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks. Importance Rank: 1 read more

Go to News Site